Rwanda

in page functions
[French]
Rwanda
Total population (2017) 12,159,563
Birth cohort (2017) 363,541
Surviving Infants (surviving to 1 year per year, 2017) 347,895
Infant mortality rate (deaths < 1 year per 1000 births, 2015) 31/1000
Child mortality rate (deaths < 5 years per 1000 births, 2015) 42/1000
World Bank Index, IDA (2015) 4.04
Gross Nation Income (per capita US$, 2015) 700
Co-financing group (2017) Initial self-financing
No. of districts/territories (2016) 30

Contact Gavi

For more info, contact Gavi country representative officer or email here

Gavi support for Rwanda

Type of support

Approvals

2001-2021 (US$)
(23 Aug 2017)

Commitments

2001-2021 (US$)
(23 Aug 2017)

Disbursements

2000-2017 (US$)
(23 Aug 2017)

% Disbursed

(23 Aug 2017)
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Total $142,880,933 $144,851,718 $137,466,946
Health system strengthening (HSS 1) $5,605,000 $5,605,000 $5,605,000 100%
Health system strengthening (HSS 2) $10,337,185 $12,307,970 $5,420,399 52%
HPV (NVS) $6,061,360 $6,061,360 $6,050,260 100%
Immunisation services support (ISS) $2,958,700 $2,958,700 $2,958,700 100%
Injection Safety Devices (NVS) $250,500 $250,500 $313,403 125%
Injection safety support (INS) $369,500 $369,500 $369,500 100%
IPV (NVS) $49,125 $49,125 $36,774 75%
Measles (NVS) $430,500 $430,500 $299,216 70%
Measles-Rubella (NVS) $3,549,500 $3,549,500 $3,622,489 102%
MR - Operational costs (OPC) $3,279,500 $3,279,500 $3,279,500 100%
MR-Follow-up campaign (NVS) $990,500 $990,500 $989,862 100%
MR-Follow-up campaign op.costs (OPC) $923,500 $923,500 $923,434 100%
Penta (NVS) $46,571,497 $46,571,497 $46,687,497 100%
Pneumo (NVS) $32,992,374 $32,992,374 $35,041,692 106%
Product Switch Grant (PSG) $88,000 $88,000
Rotavirus (NVS) $27,020,542 $27,020,542 $24,465,570 91%
Vaccine Introduction Grant (VIG) $1,403,650 $1,403,650 $1,403,650 100%

Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding

Download data for commitments, approvals & disbursements in XLS format

Rwanda DTP3 / immunisation coverage

DTP3 - WHO/UNICEF estimates (2016)

Grade of confidence


N/A
DTP3 - Official country estimates (2016) 98%
M:F sex ratio at birth (2017) 1.02
Household survey: DTP3 coverage for male (2014) 98.50%
Household survey: DTP3 coverage for female (2014) 97.80%
Household survey: Last DTP3 survey (2014) 98%
% districts achieving > 80% DTP3 coverage (2016) 100%
% districts achieving < 50% DTP3 coverage (2016) 0%
MCV WHO/UNICEF estimates (2016) 95%

Breakdown of support

Non-vaccine support Vaccine support
15% 85%
$19,960,183 $117,506,763

Data refers to disbursed values, date as per above chart

Move mouse over graph for details

News and updates relating to Rwanda

23 May 2017

Seth Q&A 1

The Best Intervention: Gavi CEO Seth Berkley's Q&A, Part I

Ahead of Seth Berkley’s speech to the 2017 graduating class at Johns Hopkins University in Washington, DC on 23 June, Global Health published a two-part Q&A with the Gavi CEO. In this first article, Seth describes Gavi’s latest priorities, highlights the increased risk of epidemics starting in densely populated urban slums and emphasises the need to reach every child with all WHO-recommended vaccines.

08 December 2016

Syrian children

Gavi to support immunisation of children in Syria

Gavi Board decisions also taken to strengthen emergency vaccine stockpiles and to accelerate human papillomavirus (HPV) vaccine programme to protect 40 million girls against cervical cancer by 2020.

14 October 2016

Zipline Delivery 1
close icon

modal window here